Tal Zaks

Tal Zaks currently serves as Chairman and CEO of Exsilio Therapeutics since January 2024 and holds several non-executive director positions at Minervax ApS, Convergent Therapeutics, Inc., PIC Therapeutics, and iECURE, inc. Tal has been a partner at OrbiMed since November 2021 and a non-executive director at Teva Pharmaceuticals since October 2021. Zaks has also contributed to academia as an Adjunct Associate Professor of Medicine at the University of Pennsylvania since July 2004. Previously, Zaks was Chief Medical Officer at Moderna Therapeutics from March 2015 to October 2021 and served on the board of Adaptimmune US from November 2016 to February 2023. Educational qualifications include a PhD in Tumor Immunology and an MD from Ben-Gurion University of the Negev, as well as a Clinical Fellowship in Hematology-Oncology from the University of Pennsylvania School of Medicine, along with an honorary Doctor of Philosophy from Bar-Ilan University.